Company profile: NeRRe Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology R&D focused on clinical and pre-clinical neurokinin receptor antagonists, including Orvepitant, a neurokinin-1 receptor antagonist in development for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). Founded in 2012 and based in Stevenage, United Kingdom.
Products and services
- Clinical Neurokinin Receptor Antagonists: NeRRe engineers clinical-stage neurokinin receptor antagonist products for therapeutic use, with capabilities in advancing candidates through clinical development pathways
- Orvepitant: An NK1-selective neurokinin-1 receptor antagonist being developed as a treatment for chronic cough associated with idiopathic pulmonary fibrosis, advancing through clinical development
- Pre-clinical Neurokinin Receptor Antagonists: NeRRe architects pre-clinical-stage neurokinin receptor antagonist products intended for subsequent clinical evaluation and therapeutic application
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeRRe Therapeutics
Fortress Biotech
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, focused on acquiring, developing and commercializing therapeutic products. Pipeline: Cosibelimab (fully human PD-L1 antibody) for EGFR mutation–positive non-small cell lung cancer; DFD-29 for inflammatory lesions of rosacea; IV Tramadol for post-surgical pain; AJ201 for spinal and bulbar muscular atrophy; BAER-101 for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fortress Biotech company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Manhattan Pharma
HQ: United States
Website
- Description: Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manhattan Pharma company profile →
Omeros
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeros company profile →
Prismic Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel prescription medical drugs for inflammatory diseases and prescription medical foods for the clinical dietary management of metabolic processes associated with disorders common in the aging 'baby boomer' population, including central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prismic Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeRRe Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeRRe Therapeutics
2.2 - Growth funds investing in similar companies to NeRRe Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeRRe Therapeutics
4.2 - Public trading comparable groups for NeRRe Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →